Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: Long-term simulation analysis using the "Diabetes Mellitus Model"

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 6, 2005, Pages 271-281

  Maxion Bergemann, S ^a   Huppertz, E ^b   Jacobs, L D ^b   Muller E ^a   Walleser, S ^a  

^a Analytica International   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Computer simulation; Diabetes mellitus type 2; Glycosylated hemoglobin A; Hypoglycemia; Insulin analogs and derivatives

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN;

ARTICLE; CLINICAL TRIAL; DIABETIC FOOT; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REGRESSION ANALYSIS; RETINA MACULA EDEMA; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 21044431963     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43271     Document Type: Article

References (30)

1. American Diabetes Association Consensus Panel 2004 Guidelines for computer modeling of diabetes and its complications. Diabetes Care 27: 2262-2264
2. Bergemann R, Suissa S, Morris A, Dineen S, Hauner H 2001 A simulation model for type 1 and 2: model description and internal validation process with UKPDS, DCCT and WESDR data. Diabetologia 44 (Suppl. 1): A114
3. Brennan A, Akehurst R 2000 Modelling in health economic evaluation: what is its place? What is its value? Pharmacoeconomics 17: 445-459
4. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I 2003 Twice daily biphasic insulin aspart improves post-prandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 5: 446-454
5. Clarke P, Gray A, Legood R, Briggs A, Holman R 2003 The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetes Med 20: 442-450
6. Clauson P, Karlander S, Steen L, Efendic S 1996 Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Diabetes Med 13: 471-477
7. DCCT 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986
8. Fritsche A, Schweitzer MA, Haring HU, 4001 Study Group 2003 Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138: 952-959
9. Hauner H, Maxion-Bergemann S, Müller E, Schulz M, Huppertz E, Bergemann R 2003 Disease management program (DMP) diabetes mellitus: simulation of therapeutic results of different guidelines. A new diabetes mellitus model. Dtsch Med Wochenschr 128: 1167-1172
10. HOE 901/2004 Study Investigators Group 2003 Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabetes Med 20: 545-551
11. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P 2003 Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 17: 307-313
12. Klein R, Klein BE, Moss SE, Cruickshanks KJ 1994 The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112: 1217-1228
13. Massi-Benedetti M, Humburg E, Dressler A, Ziemen M 2003 A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35: 189-196
14. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R 2001 Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 24: 51-55
15. Moss SE, Klein R, Klein BE 1998 The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105: 998-1003
16. Moss SE, Klein R, Klein BE 1999 The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 22: 951-959
17. Müller E, Maxion-Bergemann S, Bergemann R 2002 Long-term effective HbA1c control reduces the incidence of late diabetic complications. Simulation results from the DMM. Proceedings of the 18th Annual Meeting of the International Society of Technology Assessment in Health Care (ISTAHC Berlin 2002). Urban und Fischer, Jena, p 146
18. Müller E, Walleser S, Maxion-Bergemann S, Bergemann R 2003 The diabetes mellitus simulation model: model structure, validity and applications. Proceedings of the 19th Annual Meeting of the International Society of Technology Assessment in Health Care (ISTAHC Canmore 2003).
19. O'Brien JA, Patrick AR, Caro J 2003a Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 25: 1017-1038
20. O'Brien JA, Patrick AR, Caro J 2003b Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 3: 7
21. Raspe H, Sawicki P, Schmacke N 2004 Sind vorliegende Disease-Management-Programme für Diabetes wirklich unnötig? Gesundheit, Gesellschaft, Wissenschaft 4: 23-31
22. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators 2003 The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080-3086
23. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB 2001 Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24: 631-636
24. St. Vincent Declaration 1999 Istanbul Commitment 1999, 10th Anniversary Meeting of the St. Vincent Declaration Diabetes Action Program, Istanbul, Turkey, October 9-13 1999, http://www.idf.org/webdata/docs/SVD%20and%20Istanbul%20Commitment.pdf (last accessed Nov. 23, 2003)
25. Stehouwer MH, DeVries JH, Lumeij JA et al 2003 Combined bedtime insulin - daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate - a randomized trial. Diabetes Metab Res Rev 19: 148-152
26. Stratton IM, Adler AI, Neil HA et al 2000 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
27. Testa MA, Simonson DC 1998 Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 280: 1490-1496
28. UKPDS 33 1998 UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
29. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC 2001 Effect of improved glycemic control on health care costs and utilization. JAMA 285: 182-189
30. Yki-Järvinen H, Häring HU, Johnson E et al 2003 The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: a meta-regression analysis in type 2 diabetes. Diabetes 52 (Suppl 1). A149-150